# Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

Study · id `cardio:ct-nct02071459` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02071459](<https://clinicaltrials.gov/study/NCT02071459>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02071459

Browse, organ or system: Blood vessels  
Browse, condition area: Risk and prevention  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

## Technical summary

Registry record NCT02071459. Randomized; quadruple masking; primary purpose treatment. Start 2014-01-21 (actual); primary completion 2019-10-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 107 participants (enrolled count; ClinicalTrials.gov record NCT02071459, source copy `cardio:ctgov-nct02071459-2026-04-08`, retrieved 2026-10-31)
- Started: 2014-01-21 (actual) (ClinicalTrials.gov record NCT02071459, source copy `cardio:ctgov-nct02071459-2026-04-08`, retrieved 2026-10-31)
- Primary completion: 2019-10-28 (actual) (ClinicalTrials.gov record NCT02071459, source copy `cardio:ctgov-nct02071459-2026-04-08`, retrieved 2026-10-31)
- Completion: 2019-10-28 (actual) (ClinicalTrials.gov record NCT02071459, source copy `cardio:ctgov-nct02071459-2026-04-08`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT02071459, source copy `cardio:ctgov-nct02071459-2026-04-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02071459-2026-04-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
- Acronym: DOPS-AMS
- Condition: Multiple System Atrophy
- Intervention (Drug): L-Threo DOPS
- Intervention (Drug): placebo
- Lead sponsor: University Hospital, Toulouse
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Orthostatic hypotension (`cardio:orthostatic-hypotension`)
- Registry lists this organization as the lead sponsor: University Hospital, Toulouse (`cardio:org-university-hospital-toulouse`)

## Provenance

Content hash: d62f1ace358178b1425f97fbd618b19181d3e5434a6bfc8bd5042ef8609f6325
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
